Abstract: Abstract: "Enzymatic Process for the Preparation of (2S)-2-[(4R)-2-oxo-4-propyI pyrrolidine-l-yI]-butyric acid and its conversation into Brivaracetam" : A process for the preparation of Brivaracetam, an anti-convulsion drug, is provided comprising enzymatic conversion of (2RS)-2-[ (4R)-2-oxo-4-propyl-pyrrolidin-l-yl] butyric acid methyl ester selectively into (2S)-2- [ (4R)-2-oxo-4-propyl-pyrrolidin-l-yl] butyric acid having high chiral purity, using protease from Bacillus licheniformis. Converting the chirally pure acid into amide results in Brivaracetam.
Soft Copy Attached in PDF
| # | Name | Date |
|---|---|---|
| 1 | 202141004400-Form2 Title Page_Complete_01-02-2021.pdf | 2021-02-01 |
| 1 | 202141004400-IntimationOfGrant14-09-2023.pdf | 2023-09-14 |
| 2 | 202141004400-Form1_As Filed_01-02-2021.pdf | 2021-02-01 |
| 2 | 202141004400-PatentCertificate14-09-2023.pdf | 2023-09-14 |
| 3 | 202141004400-Description Complete_As Filed_01-02-2021.pdf | 2021-02-01 |
| 3 | 202141004400-Claims_FER Reply_27-03-2023.pdf | 2023-03-27 |
| 4 | 202141004400-Correspondence_FER Reply_27-03-2023.pdf | 2023-03-27 |
| 4 | 202141004400-Correspondence_As Filed_01-02-2021.pdf | 2021-02-01 |
| 5 | 202141004400-Form1_FER Reply_27-03-2023.pdf | 2023-03-27 |
| 5 | 202141004400-Claims_As Filed_01-02-2021.pdf | 2021-02-01 |
| 6 | 202141004400-Form3_FER Reply_27-03-2023.pdf | 2023-03-27 |
| 6 | 202141004400-Abstract_As Filed_01-02-2021.pdf | 2021-02-01 |
| 7 | 202141004400-Marked up Copies_FER Reply_27-03-2023.pdf | 2023-03-27 |
| 7 | 202141004400-Form 9_Earlier Publication_10-02-2021.pdf | 2021-02-10 |
| 8 | 202141004400-Form 5_After Filing_10-02-2021.pdf | 2021-02-10 |
| 8 | 202141004400-FER.pdf | 2023-02-28 |
| 9 | 202141004400-Correspondence_Form3_24-08-2022.pdf | 2022-08-24 |
| 9 | 202141004400-Form 18_Examination request_10-02-2021.pdf | 2021-02-10 |
| 10 | 202141004400-Correspondence_24-03-2022.pdf | 2022-03-24 |
| 10 | 202141004400-Correspondence_Request for Certified Copies_10-02-2021.pdf | 2021-02-10 |
| 11 | 202141004400-Correspondence_Form 18_10-02-2021.pdf | 2021-02-10 |
| 11 | 202141004400-Correspondence_Request Certified Copies_13-01-2022.pdf | 2022-01-13 |
| 12 | 202141004400-Correspondence_Form3_15-04-2021.pdf | 2021-04-15 |
| 12 | 202141004400-Form3_After Filing_15-04-2021.pdf | 2021-04-15 |
| 13 | 202141004400-Correspondence_Form3_15-04-2021.pdf | 2021-04-15 |
| 13 | 202141004400-Form3_After Filing_15-04-2021.pdf | 2021-04-15 |
| 14 | 202141004400-Correspondence_Form 18_10-02-2021.pdf | 2021-02-10 |
| 14 | 202141004400-Correspondence_Request Certified Copies_13-01-2022.pdf | 2022-01-13 |
| 15 | 202141004400-Correspondence_24-03-2022.pdf | 2022-03-24 |
| 15 | 202141004400-Correspondence_Request for Certified Copies_10-02-2021.pdf | 2021-02-10 |
| 16 | 202141004400-Correspondence_Form3_24-08-2022.pdf | 2022-08-24 |
| 16 | 202141004400-Form 18_Examination request_10-02-2021.pdf | 2021-02-10 |
| 17 | 202141004400-Form 5_After Filing_10-02-2021.pdf | 2021-02-10 |
| 17 | 202141004400-FER.pdf | 2023-02-28 |
| 18 | 202141004400-Marked up Copies_FER Reply_27-03-2023.pdf | 2023-03-27 |
| 18 | 202141004400-Form 9_Earlier Publication_10-02-2021.pdf | 2021-02-10 |
| 19 | 202141004400-Form3_FER Reply_27-03-2023.pdf | 2023-03-27 |
| 19 | 202141004400-Abstract_As Filed_01-02-2021.pdf | 2021-02-01 |
| 20 | 202141004400-Form1_FER Reply_27-03-2023.pdf | 2023-03-27 |
| 20 | 202141004400-Claims_As Filed_01-02-2021.pdf | 2021-02-01 |
| 21 | 202141004400-Correspondence_FER Reply_27-03-2023.pdf | 2023-03-27 |
| 21 | 202141004400-Correspondence_As Filed_01-02-2021.pdf | 2021-02-01 |
| 22 | 202141004400-Description Complete_As Filed_01-02-2021.pdf | 2021-02-01 |
| 22 | 202141004400-Claims_FER Reply_27-03-2023.pdf | 2023-03-27 |
| 23 | 202141004400-PatentCertificate14-09-2023.pdf | 2023-09-14 |
| 23 | 202141004400-Form1_As Filed_01-02-2021.pdf | 2021-02-01 |
| 24 | 202141004400-IntimationOfGrant14-09-2023.pdf | 2023-09-14 |
| 24 | 202141004400-Form2 Title Page_Complete_01-02-2021.pdf | 2021-02-01 |
| 1 | SearchreportE_27-02-2023.pdf |